Novartis quietly returns a key antibiotic to US market
There is some good news in the world of antibiotics. Novartis quietly snagged supplemental FDA approval for its drug Lamprene over the summer, transitioning a decades-old leprosy drug to the commercial market, which may boost ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.